Diuretic dose trajectories in dilated cardiomyopathy: prognostic implications

Nuzzi, V. et al. (2023) Diuretic dose trajectories in dilated cardiomyopathy: prognostic implications. Clinical Research in Cardiology, 112(3), pp. 419-430. (doi: 10.1007/s00392-022-02126-8) (PMID:36385396) (PMCID:PMC9998319)

[img] Text
284982.pdf - Published Version
Available under License Creative Commons Attribution.

[img] Text
284982Suppl.pdf - Supplemental Material



Background: For patients with heart failure, prescription of loop diuretics (LD) and of higher doses are associated with an adverse prognosis. We investigated LD dose trajectories and their associations with outcomes in patients with dilated cardiomyopathy (DCM). Methods: Associations between outcomes and both furosemide-equivalent dose (FED) at enrolment and change in FED in the subsequent 24 months were evaluated. According to FED trajectory, patients were classified as (i) dose (FED increase by ≥ 50% or newly initiated); (ii) dose↓ (FED decrease by ≥ 50%); (iii) stable dose (change in FED by < 50%); and (iv) never-users. The primary outcome was all-cause-death/heart transplantation/ventricular-assist-device/heart failure hospitalization. The secondary outcome was all-cause-death/heart transplantation/ventricular-assist-device. Results: Of 1,131 patients enrolled, 738 (65%) were prescribed LD at baseline. Baseline FED was independently associated with outcome (HR per 20 mg increase: 1.12 [95% CI 1.04–1.22, p = 0.003]. Of the 908 with information on FED within 24 months from enrolment, 31% were never-users; 29% were dose↓; 26% were stable dose and 14% were dose↑. In adjusted models, compared to never-users, stable dose had a higher risk of the primary outcome (HR 2.42 [95% CI 1.19–4.93], p = 0.015), while dose↑ had the worst prognosis (HR 2.76 [95% CI 1.27–6.03], p = 0.011). Results were similar for the secondary outcome. Compared to patients who remained on LD, discontinuation of LD (143, 24%) was associated with an improved outcome (HR 0.43 [95% CI 0.28–0.65], p < 0.001). Conclusions: In patients with DCM, LD use and increasing FED are powerful markers of adverse outcomes. Patients who never receive LD have an excellent prognosis.

Item Type:Articles
Glasgow Author(s) Enlighten ID:Cleland, Professor John and Pellicori, Dr Pierpaolo
Authors: Nuzzi, V., Cannatà, A., Pellicori, P., Manca, P., Stolfo, D., Gregorio, C., Barbati, G., Bromage, D. I., McDonagh, T., Cleland, J. G.F., Merlo, M., and Sinagra, G.
College/School:College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health
College of Medical Veterinary and Life Sciences > School of Health & Wellbeing > Robertson Centre
Journal Name:Clinical Research in Cardiology
ISSN (Online):1861-0692
Published Online:17 November 2022
Copyright Holders:Copyright © 2022 The Authors
First Published:First published in Clinical Research in Cardiology 112(3): 419-430
Publisher Policy:Reproduced under a Creative Commons licence

University Staff: Request a correction | Enlighten Editors: Update this record